logo
Plus   Neg
Share
Email

Gilead Announces NDA Submission For Filgotinib In Japan - Quick Facts

Gilead Sciences, Inc. (GILD) has submitted a New Drug Application for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults with rheumatoid arthritis, to the Japanese Ministry of Health, Labor and Welfare. The NDA is supported by data from the Phase 3 FINCH clinical trial program.

"This new drug application is an important milestone as we continue to expand Gilead's presence in Japan to now also include inflammation," said Luc Hermans, President and Representative Director, Gilead Sciences, K.K.

Filgotinib is an investigational agent and is not approved anywhere globally.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Uber Technologies Inc. (UBER) said Monday that it laid off about 350 employees across several different teams, as part of its final phase of layoffs of the process it began earlier this year. Porsche unveiled a cheaper version of its Taycan all-electric sports car, Taycan 4S. This is the third version of the sports saloon after Taycan Turbo S and Taycan Turbo launched in September. According to Porsche, Taycan 4S is now the new entry-level model in the Taycan series. The new model is available is two versions based on battery sizes. Howard University and Amazon Studios have jointly launched Howard Entertainment. The program is meant to give African-American students and other marginalized populations such as Latinx and Native American students an opportunity to train and study alongside executives in the entertainment industry. The program will begin in January 2020.
Follow RTT
>